FRONTEO AI Innovation Forum 2026 to Feature AI Drug Discovery Success Cases from Five Pharma Companies

FRONTEO Inc. will host the 'FRONTEO AI Innovation Forum 2026' on July 23, 2026, at the Nihonbashi Life Science Hub in Tokyo. Five major pharmaceutical companies—NB Health Laboratory, Santen Pharmaceutical, Fuji Pharma, Maruishi Pharmaceutical, and Meiji Seika Pharma—will present practical results from using FRONTEO's AI drug discovery service, 'Drug Discovery AI Factory (DDAIF).'

The keynote address will be delivered by non-fiction author Susumu Shimoyama. This year's theme is 'The Frontline of Drug Discovery AI Factory Implementation—From Individual Projects to Business Alliances and Co-creation.' The forum will explore the latest trends as AI application expands from research labs to executive decision-making.

[Event Overview] Date: July 23, 2026 (Thursday) - Seminar: 15:00-18:00 - Networking: 18:00-19:30 Venue: Nihonbashi Life Science Hub (Hybrid on-site/online) Capacity: Approx. 300 participants

[Program Overview] - Opening: Masahiro Morimoto (CEO, FRONTEO) - Keynote: Susumu Shimoyama - Session 1: Santen Pharmaceutical (Takazumi Taniguchi) - Session 2: Fuji Pharma (Takahiro Shimizu) - Session 3: Meiji Seika Pharma (Junya Tsujii) - Session 4: NB Health Laboratory (Yoshiyoshi Takayama) - Session 5: Maruishi Pharmaceutical (Katsuto Inoue) - Closing: Hiroyoshi Toyoshiba (CSO, FRONTEO)

FRONTEO remains committed to supporting innovative drug development and strengthening Japan’s drug discovery capabilities through its DDAIF and KIBIT solutions.